Dr. Earle Burgess on appropriate patients for PARP inhibitors in mCRPC

Video

Earle Burgess, MD, associate professor of medicine, Levine Cancer Institute, Atrium Health, explains which patients with metastatic castration-resistant prostate cancer (mCRPC) are optimal for treatment with PARP inhibitors. The PARP inhibitors olaparib (Lynparza) and rucaparib (Rubraca) are approved by the FDA for the treatment of patients with mCRPC.

Related Videos
Brian T. Helfand, MD, and Matthew Smith, MD, PhD, experts on prostate cancer
Brian T. Helfand, MD, and Matthew Smith, MD, PhD, experts on prostate cancer
blur image background of corridor in hospital or clinic image | Image Credit: © whyframeshot - stock.adobe.com
Jill M. Hamilton Reeves, PhD, RD, CSO, answers a question during a Zoom video interview
Related Content
© 2024 MJH Life Sciences

All rights reserved.